References
Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6:714-727.
Riley JK, Sliwkowski MX. CD20: a gene in search of a function. Semin Oncol. 2000;27(6 suppl 12):17-24.
Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95:3900-3908.
Wojciechowski W, Li H, Marshall S, et al. Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanisms. J Immunol. 2005;174:7859-7868.
Friess T, Herting F, Bauer S, et al. GA101, a novel therapeutic type II CD20 antibody with outstanding efficacy and clear superiority in subcutaneous non-Hodgkin lymphoma xenograft models as well as superior B cell depletion. Presented at: American Association for Cancer Research; April 12-16, 2008; San Diego, CA. Abstract 4012.
Nopora A, Preiss S, Nicolini V, et al. Contribution of enhanced ADCC to superior in vivo efficacy of the novel type II humanized, third generation CD20 antibody GA101 in NHL xenograft models. Presented at: American Association for Cancer Research; April 12-16, 2008; San Diego, CA. Abstract 3991.
Umana P, Moessner E, Bruenker P, et al. Novel 3rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction. Blood. 2006;108. Abstract 229.